乳腺良、恶性病变Ki67单克隆抗体标记观察  

Study of Ki67 Immunostaining in Benign and Malignant Breast Lesions

作　　者：张树华[1] 吴照敏[1] 李保文[1] 郑国均[1] 

机构地区：[1]滨州医学院病理学教研室,山东256603

出　　处：《临床与实验病理学杂志》1994年第4期293-295,T001,共4页Chinese Journal of Clinical and Experimental Pathology

摘　　要：本文用Ki67单克隆抗体对11例乳腺浸润性导管癌、10例乳腺良性病变做了研究。结果显示乳癌Ki67标记阳性率较高(M 12.5),良性病变较低(M 8.15),两者间差异有显著性(P=0.05)。乳癌Ki67标记阳性率与核分裂计数和核面积呈显著正相关(相关系数分别为0.849,P<0.01和0.740,P<0.01)。未发现与淋巴结转移、肿物大小和年龄之间的相关性(P>0.05)。Eleven cases of infiltrating duct carcinoma of breast and 10 cases of benign breast lesions were studied by immuostain-ing with monoclonal antibody Ki67. The re- suits showed that Ki67 labeling rates of breast carcinoma were higher ( Median 12-5), benign lesions lower (Median 8- 15) , there was a significant difference between them (P = 0. 05). The Ki67 labeling rates of breast carcinoma were related to mitotic count and nuclear area (r=0. 849,P <0. 01; r=0. 740, P<0. 01 respectively). There was not relation-ship between Ki67 labeling rates of breast carcinoma, lymph node involvement, tumor in diameter, and age (P>0. 05).

关 键 词：乳腺癌 KI67 免疫组织化学 抗体 乳腺疾病 

分 类 号：R737.903[医药卫生—肿瘤] R655.803[医药卫生—临床医学]